undamentalytics Newsletter
Sign in

Molecular Partners AG (MOLN) stock

Add to watchlist

Add holding +

NASDAQ: MOLN Nasdaq Biotechnology

E Fundamentals grade

Molecular Partners AG is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: cash-flow, stock-pay or share-count figures missing or out of date. How we value companies.

Molecular Partners AG valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds2 adding, 1 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Molecular Partners AG files

Where Molecular Partners AG stands after its latest Filing

Molecular Partners AG has little or no product revenue yet; it used $63m of cash in the twelve months. That puts it 167 of 172 for growth among the biotechnology companies we cover. The diluted share count is up 9.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 3 financial-health checks.

Our models give no value for Molecular Partners AG at present, so past values are not shown.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Molecular Partners AG's trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of -1206.3%. Where it lags: revenue growth of -100.0% ranks 167 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -100.0% (-72.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Molecular Partners AG's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Growth slowing. The growth rate is 72.0 points lower than a quarter earlier.
  • Loss-making. Operating margin is -1231.7%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 363.5 points on a year ago.
  • Burning cash. Free cash flow was -1206.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 82.6% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results

Earnings per share
-$0.31 against an average estimate of -$0.34: beat by 8.8%
Next report
August 25, 2026

Molecular Partners AG's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week-3.1%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
-1231.7%
Net margin
-1087.4%
EPS (TTM, diluted)
$-2.00

Growth

Revenue growth
−100.0%
Change in growth rate
−72.0 pts
Share count change
+9.5%

Cash

Free cash flow (TTM)
-$62.7M
FCF margin
-1206.3%
Stock pay % of revenue
82.6%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for MOLN from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Molecular Partners AG valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

Valuation models

We value Molecular Partners AG as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Molecular Partners AG with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Molecular Partners AG: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.34 −$0.31 +8.8%
Jun 2026 −$0.35 −$0.35 0.0%
Dec 2025 −$0.29 −$0.36 −22.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Nov 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Nov 2026415
  2. Oct 2026415

Counts of recommendations published by analysts covering Molecular Partners AG, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.0%
of tradable shares
Days to cover
0.35
at average volume
Short interest, 1 month
+166%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
0.0%
of shares
Employees
134
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Molecular Partners AG in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Molecular Partners AG
$0 $50M $100M $150M $200M FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY19 Q4: $20.5M Revenue (TTM), FY20 Q4: $10M Revenue (TTM), FY21 Q4: $10.7M Revenue (TTM), FY22 Q4: $198.7M Revenue (TTM), FY23 Q4: $7.8M Revenue (TTM), FY24 Q4: $5.6M Revenue (TTM), FY25 Q4: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY19 Q4 $20.5M
FY20 Q4 $10M
FY21 Q4 $10.7M
FY22 Q4 $198.7M
FY23 Q4 $7.8M
FY24 Q4 $5.6M
FY25 Q4 $0
Revenue growth, TTM YoY Molecular Partners AG
-500% 0% 500% 1000% 1500% 2000% FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY20 Q4: -51.4% Revenue growth, TTM YoY, FY21 Q4: 7.1% Revenue growth, TTM YoY, FY22 Q4: 1762.3% Revenue growth, TTM YoY, FY23 Q4: -96.1% Revenue growth, TTM YoY, FY24 Q4: -28.0% Revenue growth, TTM YoY, FY25 Q4: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY20 Q4 -51.4%
FY21 Q4 7.1%
FY22 Q4 1762.3%
FY23 Q4 -96.1%
FY24 Q4 -28.0%
FY25 Q4 -100.0%
Operating margin (TTM) Molecular Partners AG
-1500% -1000% -500% 0% 500% FY19 Q4 FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 Operating margin (TTM), FY19 Q4: -179.9% Operating margin (TTM), FY20 Q4: -624.2% Operating margin (TTM), FY21 Q4: -650.2% Operating margin (TTM), FY22 Q4: 61.5% Operating margin (TTM), FY23 Q4: -868.3% Operating margin (TTM), FY24 Q4: -1231.7% -1231.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY19 Q4 -179.9%
FY20 Q4 -624.2%
FY21 Q4 -650.2%
FY22 Q4 61.5%
FY23 Q4 -868.3%
FY24 Q4 -1231.7%
FCF margin (TTM) Molecular Partners AG
-1500% -1000% -500% 0% 500% FY19 Q4 FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FCF margin (TTM), FY19 Q4: -10.9% FCF margin (TTM), FY20 Q4: -325.7% FCF margin (TTM), FY21 Q4: -942.0% FCF margin (TTM), FY22 Q4: 61.9% FCF margin (TTM), FY23 Q4: -846.5% FCF margin (TTM), FY24 Q4: -1206.3% -1206.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q4 -10.9%
FY20 Q4 -325.7%
FY21 Q4 -942.0%
FY22 Q4 61.9%
FY23 Q4 -846.5%
FY24 Q4 -1206.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 21 10 11 199 8 6 0
Operating income −37 −62 −69 122 −68 −70 −70
Net income −37 −67 −70 124 −69 −61 −74
Diluted EPS −$1.70 −$2.68 −$2.25 $3.71 −$2.10 −$1.81 −$1.99
Growth (year on year)
Revenue — −51.4% +7.1% +>999% −96.1% −28.0% −100.0%
Operating income — — — — −155.7% — —
Net income — — — — −155.9% — —
Diluted EPS — — — — −156.7% — —
Margins
Operating margin −179.9% −624.2% −650.2% 61.5% −868.3% <−999% —
Net margin −178.0% −671.7% −653.9% 62.2% −880.7% <−999% —
Free-cash-flow margin −10.9% −325.7% −942.0% 61.9% −846.5% <−999% —
Cash flow
Cash from operations −1 −31 −99 124 −66 −67 −62
Capital spending 1 2 1 1 1 1 1
Free cash flow −2 −32 −101 123 −66 −68 −63
Stock-based pay 2 3 4 5 6 5 5
Free cash flow after stock pay −5 −36 −105 118 −72 −73 −68
Balance sheet
Cash 78 151 79 95 80 70 104
Total debt 0 0 0 0 0 0 0
Net debt (negative = net cash) −78 −151 −79 −95 −80 −70 −104
Diluted shares 21m 25m 31m 33m 33m 34m 37m
Returned to shareholders
Buybacks — 0 0 1 0 0 —
Total returned — 0 0 1 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · December 31, 2025
What it owns · $129m
Short-term assets $122mLonger-term assets $7m
What it owes, and who funded it · $129m
Short-term liabilities $14mLonger-term liabilities $14mShareholders' equity $101m
  • Short-term assets cover short-term liabilities $122m of assets due within a year against $14m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $122m short-term assets against $14m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$70m against $21,727 of interest.

From Molecular Partners AG's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2024 Q4 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$661,249
Diluted share count
+9.5%
year over year
R&D spending
977.9%
of revenue
Days sales outstanding
165 days
receivables vs revenue

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -100.0% 12.6% 167 of 172
Change in growth rate Growth -72.0pp -0.1pp 152 of 172
Operating margin Profitability -1231.7% -189.4% 139 of 175
Net margin Profitability -1087.4% -157.3% 142 of 180
Free-cash-flow margin Cash generation -1206.3% -145.4% 144 of 176
Stock pay as % of revenue Cash generation 82.6% 19.2% 132 of 179
Change in share count Balance sheet 9.5% 7.9% 89 of 156
Days sales outstanding Balance sheet 165 days 75 days 91 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$13.8M
Institutions reporting
5
Shares held vs prior quarter
▲ 0.1%
Positions opened / closed
2 / 1

Top buyers and sellers, Q2 2026: 2 institutions bought and 1 sold ; the biggest buyer was Citadel Advisors LLC (+17K shares) and the biggest seller Smartharvest Portfolios, LLC (−16K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $8.6M 2.2M 62.3% 0.0%
Bvf Inc $5.1M 1.4M 37.3% 0.0%
Citadel Advisors LLC $65,280 17K 0.5% New
Morgan Stanley $1,420 0K 0.0% 0.0%
UBS Group AG $1,080 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Molecular Partners AG's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Molecular Partners AG was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Molecular Partners AG in brief

What does Molecular Partners AG do?
Molecular Partners AG is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Molecular Partners AG's stock ticker?
Molecular Partners AG trades under the ticker MOLN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Molecular Partners AG's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Molecular Partners AG reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Molecular Partners AG's free cash flow?
Molecular Partners AG's free-cash-flow margin is -1206.3% of revenue over the trailing twelve months, ranking 144 of the 176 biotechnology companies we cover.
Who are Molecular Partners AG's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Bvf Inc and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Molecular Partners AG buying back stock, and does it pay a dividend?
Molecular Partners AG spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 9.5% over the year.